Axsome Therapeutics: A Strong Buy on Auvelity’s Robust Market ...
WEB2 hours ago · These positive commercialization metrics, coupled with consistent week-over-week prescription growth, position Auvelity—and consequently, Axsome Therapeutics—as a strong contender in the MDD ...
WEBGene therapy is forecast to be the largest next-generation segment in 2026 at $20 billion, led by Novartis’s Zolgensma (onasemnogene abeparvovec) for spinal muscular atrophy, highlighted as a...
Next-generation therapeutics sustain momentum - Nature
WEBJun 9, 2020 · Although clinical progress has boosted the number of next-generation therapeutic products on the market since 2019, our analysis of the same landscape puts the overall forecast value in 2024...
Therapeutic proteins: developments, progress, challenges, and …
WEBMar 18, 2024 · This review provides comprehensive information on various sources and production of therapeutic proteins. The review also summarizes the challenges currently faced by scientists while developing protein-based therapeutics, along with …
Tracking Pharma Growth: Leading Therapeutic Sectors
WEBMay 19, 2022 · Oncology and three other therapeutic areas (immunology, anti-diabetics, and anti-thrombotics) accounted for nearly all of global growth of innovative brands in 2020–2021, which was dominated by developed markets (as measured at ex-manufacturers’ prices).
Therapeutic peptides: current applications and future directions
WEBFeb 14, 2022 · Therapeutic peptides commonly act as hormones, growth factors, neurotransmitters, ion channel ligands, or anti-infective agents.
The Limitless Future of RNA Therapeutics - PMC - National …
WEBMar 18, 2021 · The rapid growth of mRNA therapeutics has been made possible by recent advances which have overcome key obstacles such as innate immune activation, RNA stability, and delivery.
The growth of siRNA-based therapeutics: updated clinical studies
WEBIntroduction. RNA interference (RNAi), a regulatory mechanism of most eukaryotic cells to directly control gene activity, has become a mechanism of drug action in the development of RNAi-based therapies [1, 2].
Life Sciences’ Contribution to the US Digital Therapeutics Market …
WEBAug 9, 2021 · The US digital therapeutics market is estimated to witness more than three-and-a-half-fold growth reaching $4.54 billion by 2025, at a CAGR of 29.8%, finds Frost & Sullivan.
CRISPR Therapeutics Highlights Strategic Priorities and 2024 …
WEBJan 8, 2024 · CRISPR Therapeutics begins 2024 in a strong financial position with approximately $1.9 billion in cash, cash equivalents and marketable securities, which is inclusive of a $200 million milestone payments received in January related to the FDA approval of CASGEVY.